Skip to content

13F-HR filed by Euclidean Capital LLC

Euclidean Capital LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 13 holding rows worth $888,536,292.

Accession
0001012975-24-000089
Filed
2024-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2023

A holdings report, 13 entries on the cover page, a total value of $888,536,292 stated on the cover page (in dollars after the unit check, H1), rows summing to $888,536,292 with VALUE read as dollars as filed, 13F file number 028-20777. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPY78462F103SHS917,141$435,926,289dollars as filed
SPDR GOLD TR78463V107GOLD SHS1,390,000$265,726,300dollars as filed
ISHARES TR46429B598MSCI INDIA ETF2,425,144$118,371,279dollars as filed
RAPT THERAPEUTICS INC75382E109COM657,899$16,348,790dollars as filed
ALECTOR INC014442107COMMON STOCK1,307,858$10,436,707dollars as filed
FOGHORN THERAPEUTICS INC344174107COMMON STOCK1,573,761$10,150,758dollars as filed
23ANDME HOLDING CO90138Q108CLASS A COM10,243,122$9,357,092dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM989,410$9,102,572dollars as filed
PMV PHARMACEUTICALS INC69353Y103COM2,627,643$8,145,693dollars as filed
TENAYA THERAPEUTICS INC87990A106COM1,015,705$3,290,884dollars as filed
NGM BIOPHARMACEUTICALS INC62921N105COM992,168$852,272dollars as filed
SURROZEN INC86889P208COMMON STOCK87,696$824,342dollars as filed
SURROZEN INC86889P117*W EXP 08/01/203170,833$3,314dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-24-000089this filing2024-02-14acceptance time not in the bulk data set